Skip to main content
NCBI home page
Heart logoLink to Heart
. 1999 Jul;82(1):47–51. doi: 10.1136/hrt.82.1.47

Ten year survival after heart transplantation: palliative procedure or successful long term treatment?

S Fraund 1, K Pethig 1, U Franke 1, T Wahlers 1, W Harringer 1, J Cremer 1, H Fieguth 1, P Oppelt 1, A Haverich 1
PMCID: PMC1729113  PMID: 10377308

Abstract

OBJECTIVE—To investigate the long term outcome and prognostic factors after heart transplantation.
SETTING—University hospital.
SUBJECTS—120 heart transplant patients (98 male, 22 female; underlying disease: dilated cardiomyopathy in 69, coronary artery disease in 42, miscellaneous in nine) who had undergone heart transplantation between October 1984 and October 1987. Immunosuppressive treatment was comparable in all patients and rejection episodes were treated in a uniform manner.
METHODS—Functional status, quality of life, and potential predictors for long term survival were investigated.
RESULTS—Actuarial survival rates were 65% at five years and 48% at 10 years; 58 patients survived > 10 years. The major causes of death were cardiac allograft vasculopathy (39%), acute rejection (18%), infection (11%), and malignancy (11%). Long term survivors had good exercise tolerance assessed by the New York Heart Association classification: 47 (81%) in grade I/II; 11 (19%) in grade III/IV. Echocardiography showed good left ventricular function in 48 patients. On angiography, severe allograft vasculopathy was present in only 16 patients (28%). Renal function was only slightly impaired, with mean (SD) serum creatinine of 148.5 (84.9) µmol/l. Multiple potential predictors of long term survival were analysed but none was found useful.
CONCLUSIONS—Heart transplantation represents a valuable form of treatment. Survival for more than 10 years with a good exercise tolerance and acceptable side effects from immunosuppression can be achieved in about 50% of patients.


Keywords: heart transplantation; long term survival

Full Text

The Full Text of this article is available as a PDF (127.5 KB).

Figure 1  .

Figure 1  

Open in a new tab

10 year actuarial survival rates computed by Kaplan-Meier estimate: * — *, dilated cardiomyopathy as the underlying disease; • — •, coronary artery disease as the underlying disease.

Figure 2  .

Figure 2  

Open in a new tab

(A) Causes of death in group as a whole; (B) causes of death in year 1. 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bourge R. C., Kirklin J. K., Naftel D. C., McGiffin D. C. Predicting outcome after cardiac transplantations: lessons from the Cardiac Transplant Research Database. Curr Opin Cardiol. 1997 Mar;12(2):136–145. doi: 10.1097/00001573-199703000-00008. [DOI] [PubMed] [Google Scholar]
  2. Chenzbraun A., Pinto F. J., Alderman E. L., Botas J., Oesterle S. N., Schroeder J. S., Valantine H., Popp R. L. Distribution and morphologic features of coronary artery disease in cardiac allografts: an intracoronary ultrasound study. J Am Soc Echocardiogr. 1995 Jan-Feb;8(1):1–8. doi: 10.1016/s0894-7317(05)80351-7. [DOI] [PubMed] [Google Scholar]
  3. Cohn J. N., Archibald D. G., Ziesche S., Franciosa J. A., Harston W. E., Tristani F. E., Dunkman W. B., Jacobs W., Francis G. S., Flohr K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  4. Cohn J. N., Franciosa J. A. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977 Jul 7;297(1):27–31. doi: 10.1056/NEJM197707072970105. [DOI] [PubMed] [Google Scholar]
  5. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  6. De Mattos A. M., Head M. A., Everett J., Hosenpud J., Hershberger R., Cobanoglu A., Ott G., Ratkovec R., Norman D. J. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used. Transplantation. 1994 Feb 27;57(4):626–630. [PubMed] [Google Scholar]
  7. Franciosa J. A., Wilen M., Ziesche S., Cohn J. N. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983 Mar 1;51(5):831–836. doi: 10.1016/s0002-9149(83)80141-6. [DOI] [PubMed] [Google Scholar]
  8. Franciosa J. A., Wilen M., Ziesche S., Cohn J. N. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983 Mar 1;51(5):831–836. doi: 10.1016/s0002-9149(83)80141-6. [DOI] [PubMed] [Google Scholar]
  9. Frist W. H., Stinson E. B., Oyer P. E., Baldwin J. C., Shumway N. E. Long-term hemodynamic results after cardiac transplantation. J Thorac Cardiovasc Surg. 1987 Nov;94(5):685–693. [PubMed] [Google Scholar]
  10. Gao S. Z., Alderman E. L., Schroeder J. S., Silverman J. F., Hunt S. A. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988 Aug;12(2):334–340. doi: 10.1016/0735-1097(88)90402-0. [DOI] [PubMed] [Google Scholar]
  11. Hausen B., Demertzis S., Rohde R., Albes J. M., Schäfers H. J., Borst H. G. Low-dose cyclosporine therapy in triple-drug immunosuppression for heart transplant recipients. Ann Thorac Surg. 1994 Oct;58(4):999–1004. doi: 10.1016/0003-4975(94)90444-8. [DOI] [PubMed] [Google Scholar]
  12. Hosenpud J. D., Novick R. J., Bennett L. E., Keck B. M., Fiol B., Daily O. P. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report--1996. J Heart Lung Transplant. 1996 Jul;15(7):655–674. [PubMed] [Google Scholar]
  13. Johnson D. E., Gao S. Z., Schroeder J. S., DeCampli W. M., Billingham M. E. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 1989 Sep-Oct;8(5):349–359. [PubMed] [Google Scholar]
  14. Kobashigawa J. A., Katznelson S., Laks H., Johnson J. A., Yeatman L., Wang X. M., Chia D., Terasaki P. I., Sabad A., Cogert G. A. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995 Sep 7;333(10):621–627. doi: 10.1056/NEJM199509073331003. [DOI] [PubMed] [Google Scholar]
  15. McKee P. A., Castelli W. P., McNamara P. M., Kannel W. B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441–1446. doi: 10.1056/NEJM197112232852601. [DOI] [PubMed] [Google Scholar]
  16. O'Connell J. B., Bourge R. C., Costanzo-Nordin M. R., Driscoll D. J., Morgan J. P., Rose E. A., Uretsky B. F. Cardiac transplantation: recipient selection, donor procurement, and medical follow-up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1992 Sep;86(3):1061–1079. doi: 10.1161/01.cir.86.3.1061. [DOI] [PubMed] [Google Scholar]
  17. Oyer P. E. Heart transplantation in the cyclosporine era. Ann Thorac Surg. 1988 Nov;46(5):489–490. doi: 10.1016/s0003-4975(10)64681-4. [DOI] [PubMed] [Google Scholar]
  18. Packer M., Carver J. R., Rodeheffer R. J., Ivanhoe R. J., DiBianco R., Zeldis S. M., Hendrix G. H., Bommer W. J., Elkayam U., Kukin M. L. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991 Nov 21;325(21):1468–1475. doi: 10.1056/NEJM199111213252103. [DOI] [PubMed] [Google Scholar]
  19. Pethig K., Heublein B., Wahlers T., Haverich A. Mechanism of luminal narrowing in cardiac allograft vasculopathy: inadequate vascular remodeling rather than intimal hyperplasia is the major predictor of coronary artery stenosis. Working Group on Cardiac Allograft Vasculopathy. Am Heart J. 1998 Apr;135(4):628–633. doi: 10.1016/s0002-8703(98)70278-9. [DOI] [PubMed] [Google Scholar]
  20. Ratkovec R. M., Wray R. B., Renlund D. G., O'Connell J. B., Bristow M. R., Gay W. A., Jr, Karwande S. V., Doty D. B., Millar R. C., Menlove R. L. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation. J Thorac Cardiovasc Surg. 1990 Jul;100(1):6–12. [PubMed] [Google Scholar]
  21. Schroeder J. S., Hunt S. A. Cardiac transplantation: where are we? N Engl J Med. 1986 Oct 9;315(15):961–963. doi: 10.1056/NEJM198610093151511. [DOI] [PubMed] [Google Scholar]
  22. Smith J. D., Rose M. L., Pomerance A., Burke M., Yacoub M. H. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet. 1995 Nov 18;346(8986):1318–1322. doi: 10.1016/s0140-6736(95)92341-1. [DOI] [PubMed] [Google Scholar]
  23. von Scheidt W., Ziegler U., Kemkes B. M., Reichart B., Erdmann E. Long-term myocardial function after heart transplantation. Thorac Cardiovasc Surg. 1993 Jun;41(3):156–162. doi: 10.1055/s-2007-1013845. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES